File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant

TitleChemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant
Authors
KeywordsEfficacy
Meta-analysis
Nasopharyngeal carcinoma
Sequence
Chemotherapy
Toxicity
Issue Date2015
Citation
Current Treatment Options in Oncology, 2015, v. 16, n. 9, article no. 44 How to Cite?
Abstract© 2015, Springer Science+Business Media New York. Nasopharyngeal cancers are unique among other head and neck cancers, not only in epidemiology and histological characteristics, but also on treatment strategies as well. Radiotherapy is the primary treatment due to its radiosensitivity. In locally advanced stages, concurrent chemoradiation has been established to be effective to eradicate the disease and improve survival, in favor of radiotherapy alone. While increasing studies have explored the potential benefit of adding more chemotherapy to the concurrent regimen, whether adjuvant or neoadjuvant, it is generally agreed that proper patient selection is needed to stratify high-risk groups to intensify treatment and to optimize the disease outcome. Future studies are ongoing, possibly with the addition of biomarkers such as EBV DNA for risk group stratification. Refinement of patient groups that should be selected for combined modality treatment in stage II disease is also warranted.
Persistent Identifierhttp://hdl.handle.net/10722/214073
ISSN
2015 Impact Factor: 2.127
2015 SCImago Journal Rankings: 1.303

 

DC FieldValueLanguage
dc.contributor.authorNg, Wai Tong-
dc.contributor.authorChang, Amy T Y-
dc.contributor.authorLee, Sarah W M-
dc.contributor.authorSze, Henry C K-
dc.contributor.authorLee, Anne W M-
dc.date.accessioned2015-08-19T13:41:46Z-
dc.date.available2015-08-19T13:41:46Z-
dc.date.issued2015-
dc.identifier.citationCurrent Treatment Options in Oncology, 2015, v. 16, n. 9, article no. 44-
dc.identifier.issn1527-2729-
dc.identifier.urihttp://hdl.handle.net/10722/214073-
dc.description.abstract© 2015, Springer Science+Business Media New York. Nasopharyngeal cancers are unique among other head and neck cancers, not only in epidemiology and histological characteristics, but also on treatment strategies as well. Radiotherapy is the primary treatment due to its radiosensitivity. In locally advanced stages, concurrent chemoradiation has been established to be effective to eradicate the disease and improve survival, in favor of radiotherapy alone. While increasing studies have explored the potential benefit of adding more chemotherapy to the concurrent regimen, whether adjuvant or neoadjuvant, it is generally agreed that proper patient selection is needed to stratify high-risk groups to intensify treatment and to optimize the disease outcome. Future studies are ongoing, possibly with the addition of biomarkers such as EBV DNA for risk group stratification. Refinement of patient groups that should be selected for combined modality treatment in stage II disease is also warranted.-
dc.languageeng-
dc.relation.ispartofCurrent Treatment Options in Oncology-
dc.subjectEfficacy-
dc.subjectMeta-analysis-
dc.subjectNasopharyngeal carcinoma-
dc.subjectSequence-
dc.subjectChemotherapy-
dc.subjectToxicity-
dc.titleChemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s11864-015-0361-5-
dc.identifier.scopuseid_2-s2.0-84938058289-
dc.identifier.hkuros254891-
dc.identifier.volume16-
dc.identifier.issue9-
dc.identifier.spagearticle no. 44-
dc.identifier.epagearticle no. 44-
dc.identifier.eissn1534-6277-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats